996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

  • Imfinzi Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
    February 10, 2021
    The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service